Marc Gurwith

Dr. Marc Gurwith is chief medical officer for Verndari, Inc., a biopharmaceutical company based in Napa, California, that aims to transform global healthcare through next-generation vaccine science.

Prior to Verndari, Dr. Gurwith was chief medical officer for PaxVax, Inc., a company based in Redwood City, California, focused on developing, manufacturing and commercializing specialty vaccines that protect against existing and emerging infectious diseases. PaxVax was later sold to Emergent BioSolutions in 2018.

Dr. Gurwith previously served as senior vice president of Medical Affairs and chief medical officer of VaxGen, a biopharmaceutical company based in the San Francisco Bay Area that engaged in the development of vaccines that immunize against infectious disease. At VaxGen, Dr. Gurwith ran clinical trials for vaccines aimed at influenza, anthrax, smallpox, and HIV.

He has also served as chief medical officer of Genelabs; vice president at Sequus Pharmaceuticals, Inc.; vice president of medical and scientific affairs at Boeheringer-Mannheim; and senior director of clinical research at Wyeth-Ayerst Research.

Dr. Gurwith received a B.A. in Philosophy from Yale University in 1961. He received an M.D. from Harvard University Medical School in 1965. He received a J.D. from the James E. Beasley School of Law at Temple University in 1991.